The MMRF's Latest Interim Analysis from the CoMMpass Study and What it Means for Myleoma Patients - Multiple Myeloma Research Foundation

The MMRF’s Latest Interim Analysis from the CoMMpass Study and What it Means for Myleoma Patients

participants-in-the-MMRF-commpass-studyWhether you are a myeloma patient, or a caregiver, you know how valuable the support of a community can be. By participating, you are providing valuable data and insights to the patient community by sharing your experiences and offering support.

Similarly, when you participate in studies, you are providing valuable data and insights to researchers who are helping to find a cure for myeloma. When you participate in the MMRF’s CoMMpass Study℠ (CoMMpass), you’re helping us create a global community of patients, clinicians and researchers who are working together to extend the lives of myeloma patients everywhere.

Many of you have probably heard of CoMMpass before – it is a research study involving patients with newly diagnosed active multiple myeloma. The goal is to map the genomic profile of up to 1,000 myeloma patients at diagnosis, and at multiple points throughout the course of the disease, helping researchers to understand how each patient responds to different treatments over time.

We strongly believe that providing researchers and clinicians around the world with access to data from CoMMpass will revolutionize the way multiple myeloma is treated.

Every six months, we provide researchers and clinicians with updated data through our Researcher Gateway. Similar to the Community Gateway, this is an online portal that allows researchers and clinicians to easily exchange and share data with one another.

The fifth data release – or interim analysis as you may see it referred to – occurred in March 2015. Genomic data from 190 participants was made available on the Researcher Gateway. This data will help researchers to identify new genomic changes in myeloma throughout the course of the disease.

The data also included the first comparisons of molecular changes that occurred at diagnosis and at points of progression from the same patient. This means that researchers will be able to better understand how myeloma changes over time in a specific patient, allowing healthcare professionals to adjust the course of treatment based on the patient’s genetic profile.

This is just a start and we are excited to continually provide the research community with new data to better understand how different patients respond to specific therapies. We hope to use this data to help develop personalized treatments for myeloma that target the underlying cause of the disease –meaning better care for you.

Want to learn more about CoMMpass? Contact one of our nurse specialists at 866-603-6628.

Posted: May 04, 2015

3 thoughts on “The MMRF’s Latest Interim Analysis from the CoMMpass Study and What it Means for Myleoma Patients

  1. Anne-Marie Olmedo says:

    I would likee and find out more about CoMMpass and research. I was newly diagnosed with Multiple Myeloma in November 2015. On first round chemo and BMT at City of Hope July 2015


  2. Teresa Frederick says:

    Good Morning,
    I was diagnosed with multiple myeloma in 2009, and certainly would be happy to participate in a study?
    Please let me know, how I can join? Thanks for your help?
    Terry Frederick


  3. Rodney Perera says:

    My wife 66 years old was diagnosed with M/Myeloma January 2016. According to the Oncologist at National Cancer Institute, Colombo, Sri Lanka, who treat her, had been classified as stage 1. She was under treatments since then with Morphine 30mg ,Prednisalon 60mg and Thalidomide 100mg, which still continues. Latter two are prescribed for the first 4 days of every 6 weeks. Haemoglobin had improved from 8.7 to 10.7 during the last 7 months.
    Last month, she had an attack of Benign Positional Vertico. Other than that, she complains of a severe back pain, with a apparent bend of the hip. We wish to join your study and feed back.


Leave a Reply

Your email address will not be published. Required fields are marked *